CoChat

Tempered Enthusiasm for Fecal Transplant

Open access
Solari, P. R., Fairchild, P. G., Noa, L. J., Wallace, M. R. · 2014 · Clinical Infectious Diseases
Cited by 72

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

To theEditor—The attraction of fecal microbiota transplant (FMT) as a treatment for Clostridium difficile infection (CDI) is based on reported efficacy and safety [1, 2]. At our institution, we had used FMT in 10 refractory cases without complication. Our most recent FMT has tempered our enthusiasm. A 68-year-old man with advanced oropharyngeal cancer necessitating gastric tube (G-tube) feeding, diabetes mellitus, and coronary artery disease was treated twice in the preceding 6 months at another institution for severe CDI. His first episode had been complicated by shock and was treated with intravenous metronidazole, fidaxomicin, and a prolonged taper of vancomycin. Subsequently, he relapsed with C. difficile–associated septic shock (toxin positive, pseudomembranes). This second life-threatening C. difficile episode was treated with intravenous metronidazole and tigecycline as well as fidaxomicin. After 18 days, the patient transferred to our hospital for FMT. On arrival he was afebrile, hemodynamically stable, and in no distress, but was having frequent loose stools. His abdomen was moderately distended without tenderness; anasarca was noted. A G-tube was in place. His white blood cell (WBC) count was 9.7 × 103/µL, creatinine level was 1.4 mg/dL, and stool C. difficile polymerase chain reaction (Cephacid) was positive. Abdominal computed tomography (CT) demonstrated diffuse pancolitis without dilatation. He was receiving fidaxomicin via G-tube and intravenous metronidazole. After obtaining consent from the patient, we proceeded with FMT. The spouse served as the donor. As per our protocol, she was screened for human immunodeficiency virus, hepatitis A, B, and C viruses, cytomegalovirus, and C. difficile. Sixty grams of donor stool was mixed with 70 mL of saline, filtered twice, and infused via a gastrojejunostomy tube placed through the G-tube. The position of the tip of the gastrojejunostomy tube near the ligament of Treitz was confirmed by contrast injection under fluoroscopy and routine abdominal radiography just prior to the fecal instillation. The procedure itself was uncomplicated, and all antimicrobials were stopped after the FMT. During the first 48 hours after FMT, the patient had no abdominal pain, he was afebrile and hemodynamically stable, and his stools were “thicker” than before FMT. Early on the third day after FMT, the patient noted recurrent abdominal pain. He was newly hypotensive (blood pressure 68/41 mm Hg), tachycardic (140 beats per minute), and tachypneic (28 breaths per minute). His WBC count was 600 × 103/µL, and blood cultures grew Pseudomonas aeruginosa, Escherichia coli, and Lactobacillus casei. A CT scan revealed a dilated colon (10 cm) and pneumoperitoneum. During an emergent surgical procedure, it was found that the G-tube was dislodged, producing the free air; there was no bowel perforation or overt peritonitis. The massively dilated colon was resected, but the patient's septic shock proved refractory to aggressive intensive care and he died on the fourth day after FMT. One of the selling points of FMT for refractory CDI has been its safety. To our knowledge, only a single case of attributable death (due to aspiration pneumonia) has been reported after FMT [3]. Our patient decompensated with toxic megacolon and shock 48 hours after FMT. The reason for this precipitous decline is unclear. Perhaps the abrupt discontinuation of C. difficile therapy after FMT contributed, but to continue antimicrobials after FMT seemed counterintuitive. Following this death, we have modified our FMT consent form to include the possibility of catastrophic post-FMT colitis, sepsis, and death. Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/ciu278

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

Metadata

Authors
Solari, P. R., Fairchild, P. G., Noa, L. J., & Wallace, M. R.
Venue
Clinical Infectious Diseases
Published
2014-04-23
Volume
59
Issue
2
Pages
319-319
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2093207028
Cited by
72
References
1
FWCI
6.49
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.